



truScreen
a world without
cervical cancer

NZX/ASX Announcement

3 August 2022

TruScreen-based cervical cancer screening centre opens in Mexico City

Key Highlights

- A TruScreen-based cervical cancer screening centre has opened in Ciudad de Mexico (Mexico City), operated by Mexpharm Medical Clinical.
- Mexpharm Medical Clinical is a leading healthcare provider in Mexico, specialising in comprehensive medical care focussed on the needs of patients and clinicians.
- The centre will showcase TruScreen's medical technology, act as a training centre, and provide screening services to local People.
- The centre's opening will further expand TruScreen's footprint in a significant marketplace, with the female population in Mexico now around 65 million.

TruScreen Group Limited (NZX/ASX: TRU) ('TruScreen' or 'the Company') is pleased to announce the establishment of a TruScreen-based cervical cancer screening centre in a new clinic in Ciudad de Mexico (Mexico City) operated by leading healthcare provider Mexpharm Medical Clinical.

The new clinic will use the TruScreen device for cervical cancer screening

Mexpharm Medical Clinical, a leader in healthcare care in Mexico, specialises in comprehensive medical care focused on the needs of patients and clinicians. It provides state-of-the-art medical technologies and doctors specialized in ophthalmology, endoscopy, gynecology-oncology, internal medicine, anesthesiology, and general medicine. It delivers competitively priced, quality short-stay medical care with high level of professional medical care. The agreement to operate the TruScreen-based cervical cancer screening centre in the Mexpharm clinic was negotiated by the Company's distributor in Mexico, Sunbird S.A. de C.V.



Figure 1: The waiting room in the Mexpharm clinic



truscreen
a world without
cervical cancer




Figure 2: The TruScreen cervical cancer screening operator in the Mexpharm clinic

The TruScreen package being supplied to Mexpharm

The centre will showcase TruScreen's medical technology, act as a training centre, and provide screening services to local people. It follows on TruScreen's establishment of a service centre in Mexico during the 2022 financial year, obviating the need for medical devices to be returned to Australia for service and re-calibration.

TruScreen's addressable market in Mexico is significant

Mexico has reported strong population growth for many years with a population of around 130 million. About 22 million residing in Mexico City. Within the total population number, more than 65 million are female, of whom around half fall within the prime cervical cancer screening age of 25-64 years old.¹




Figure 3: Mexico's population is around 130m (Data Source: The World Bank)

¹ https://cdn.who.int/media/docs/default-source/country-profiles/cervical-cancer/cervical-cancer-mex-2021-country-profile-en.pdf?sfvrsn=8a0b4124_38&download=true

For personal use only

MEXICO

CERVICAL CANCER PROFILE

Morbidity and Mortality

Crude cervical cancer incidence per 100 000 women (2020):	14.3
Age-standardized cervical cancer incidence per 100 000 women (2020):	12.6
Cumulative risk of cervical cancer, ages 0-74 (2020):	1.3%
Cervical cancer deaths (2019):	4 800
Cervical cancer mortality-to-incidence ratio (2020):	0.46
Population-based cancer registry exists (2021):	Yes

Figure 4: Cervical cancer profile in Mexico (Source: World Health Organisation)

According to the hpvcentre.net, Mexico has a population of almost 50 million women ages 15 years and older who are at risk of developing cervical cancer. Current estimates indicate that every year 9,439 women are diagnosed with cervical cancer and 4,335 die from the disease. Cervical cancer ranks as the second most frequent cancer among women in Mexico and the third most frequent cancer among women between 15 and 44 years of age.²

TruScreen CEO Juliet Hull said: “We are thrilled to partner with highly respected healthcare group Mexpharm Medical Clinical. The TruScreen-based cervical cancer screening centre in their new clinic in Mexico City will further build on our existing presence in the huge Mexican market. We look forward to using it to showcase our unique medical technology and provide cervical cancer screening services to local businesses. While doing this, the centre will also be an ideal base to provide training services.”

Sunbird S.A. de C.V Managing Director Dr. Francisco José Camargo Santacruz said: “Sunbird is delighted to be part of TruScreen’s ongoing expansion into the large Mexican market. We are particularly proud to have played a role in the evolving partnership between TruScreen and Mexpharm. The innovative clinic they have set up together represents a quantum leap in the quality of women’s health in Mexico. And the upside potential for TruScreen flowing from the partnership is immense, with the female population in this major Central American country currently around 65 million. It opens the door to a potential new business model, where TruScreen builds scale and materially grows its Single Use Sensor (SUS) sales into the Mexican market.”

This announcement has been approved by the Board.

-ENDS-

For more information, visit www.truscreen.com or contact:

Juliet Hull
Chief Executive Officer
juliethull@truscreen.com

Guy Robertson
Chief Financial Officer
guyrobertson@truscreen.com

Julia Maguire
Investor Relations
julia@thecapitalnetowrk.com.au
+61 2 8999 3699

² https://hpvcentre.net/statistics/reports/MEX_FS.pdf

For personal use only

About TruScreen:

TruScreen Group Limited (NZX/ASX: TRU) is a New Zealand-based medical device company that has developed an AI-enabled device that can detect precancerous and cancerous cervical changes in real-time via optical and electrical measurements of cervical tissue. Unlike many cervical screening technologies that have only triage/adjunct functionality, the TruScreen device is registered as a primary screening tool.

TruScreen's cervical screening technology effectively resolves many of the ongoing issues with conventional cytology, including failed samples, poor patient follow-up, patient discomfort from sample collections, and the need for supporting laboratory infrastructure.

The device is CE-marked, meaning it meets EU safety, health and environmental protection standards required for sale and use throughout Europe. It is also National Medical Products Administration approved for sale in China.

TruScreen is currently targeting product sales to low and middle-income countries, including China, Mexico, Vietnam, Russia, Czech Republic, Poland, Serbia, Bosnia, Macedonia, and Saudi Arabia, where no large-scale cervical cancer screening programs and infrastructure are currently in place. By doing so, the Company hopes to help improve the health and wellbeing of women worldwide.

To learn more, please visit: www.truscreen.com/

For personal use only